Table 1.
Univariate and multivariate analyses of factors associated with response to immunotherapy in the melanoma cohort.
| Statistics | Crude Analysis | Adjust Analysis | |||
|---|---|---|---|---|---|
| OR (95%CI) | p Value a | OR (95%CI) | p Value a | ||
| APOL6 expression b | |||||
| Low | 31 (50.0%) | 1 | 1 | ||
| High | 31 (50.0%) | 9.35 (2.63, 33.26) | <0.01 | 12.46 (3.11, 50.01) | <0.01 c |
| Treatment regimen | |||||
| PD1 | 35 (56.5%) | 1 | |||
| PD1 plus CTLA4 | 27 (43.5%) | 2.95 (0.96, 9.08) | 0.06 | ||
| Biopsy Site | |||||
| Subcutaneous | 38 (61.3%) | 1 | |||
| Lymph node | 17 (27.4%) | 0.74 (0.23, 2.41) | 0.62 | ||
| Others | 7 (11.3%) | 1.30 (0.22, 7.64) | 0.77 | ||
| Age | 62.3 ± 14.1 | 1.00 (0.96, 1.04) | 0.95 | ||
| Sex | |||||
| Male | 39 (62.9%) | 1 | |||
| Female | 23 (37.1%) | 1.43 (0.48, 4.28) | 0.52 | ||
a p values are derived from univariate and multivariate logistic regression models. b Low and high, respectively, indicate lower than or higher than the mean expression level of APOL6 among the whole melanoma cohort. c Adjusted for treatment regimen.